

## Supplemental materials

### Material and Methods

**Table S1.** COVID-19 vaccines delivery timeline in the European and Italian pediatric population updated up to the end of June 2020 (end of the study).

<u>Type of vaccine</u>	<u>Age group</u>	<u>EMA* authorization</u>	<u>AIFA* authorization</u>	<u>Primary regimen schedule and doses</u>	<u>Extension of indication for use as a booster approved by AIFA</u>
<b>Cominarty (BioNTech/Pfizer's vaccine)</b>	16 and older	December, 21th, 2020 <sup>1</sup>	December, 22th, 2020 <sup>2</sup>	30 mcg/dose, 2 doses cycle 21 days away from each other	December, 6th, 2021; 30 mcg/dose, independently from the previous type of vaccine administered, at least 4 months away from the completion of the primary cycle <sup>3</sup>
<b>Cominarty (BioNTech/Pfizer's vaccine)</b>	12-15 years old	May, 28 th, 2021 <sup>4</sup>	June, 4 th, 2021 <sup>5</sup>	30 mcg/dose, 2 doses cycle 21 days away from each other	January, 5 th, 2022; 30 mcg/dose, independently from the previous type of vaccine administered, at least 4 months away from the completion of the primary cycle <sup>6</sup>
<b>Spikevax (previously</b>	12-17 years old	July, 23 th, 2021 <sup>7</sup>	July, 29 th, 2021 <sup>8</sup>	100 mcg/dose, 2 doses	Not approved

<b>COVID-19 vaccine Moderna)</b>				cycle 28 days away from each other	
<b>Cominarty (BioNTech/Pfizer's vaccine)</b>	5-11 years old	November, 25 th, 2021 <sup>9</sup>	December 1 st, 2021 <sup>10</sup>	10 mcg/dose, 2 doses cycle 21 days away from each other	<u>Not approved</u>
<b>Spikevax (previously COVID-19 vaccine Moderna)</b>	5-11 years old	<u>Not approved</u>	<u>Not approved</u>		<u>Not approved</u>

\*European Medicines Agency (EMA); Agenzia Italiana del Farmaco (AIFA);

## References

- 1 First COVID-19 vaccine approved for children aged 12 to 15 in EU | European Medicines Agency, available at:  
<https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty#:~:text=Comirnaty%20received%20a%20conditional%20marketing,authorisation%20on%2010%20October%202022.>
- 2 La Commissione Tecnico Scientifica di AIFA (CTS) approva il vaccino BioNTech/Pfizer. Comunicato AIFA n. 620 22 dicembre 2020, available at  
[https://www.aifa.gov.it/documents/20142/0/Comunicato%20AIFA%20n.%20620%20-%20Autorizzato%20il%20vaccino%20BioNTech%20Pfizer.%20Sul%20sito%20AIFA%20risposte%20alle%20domande%20pi%C3%B9%20frequenti\(1\).pdf](https://www.aifa.gov.it/documents/20142/0/Comunicato%20AIFA%20n.%20620%20-%20Autorizzato%20il%20vaccino%20BioNTech%20Pfizer.%20Sul%20sito%20AIFA%20risposte%20alle%20domande%20pi%C3%B9%20frequenti(1).pdf)
- 3 La Commissione Tecnico Scientifica di AIFA (CTS) approva la dose booster con il vaccino Comirnaty per la fascia di età a partire dai 16 anni. Available at  
<https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&codLeg=84077&parte=1%20&serie=null>
- 4 First COVID-19 vaccine approved for children aged 12 to 15 in EU | European Medicines Agency. <https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu>
- 5 La Commissione Tecnico Scientifica di AIFA (CTS) approva l'utilizzo del vaccino Comirnaty per la fascia di età 12-15 anni. Comunicato AIFA n. 647 31 maggio 2021, available at  
[https://www.aifa.gov.it/documents/20142/1289678/Comunicato\\_stampAIFA\\_n.647.pdf](https://www.aifa.gov.it/documents/20142/1289678/Comunicato_stampAIFA_n.647.pdf)
- 6 La Commissione Tecnico Scientifica di AIFA (CTS) approva la dose booster con il vaccino Comirnaty per la fascia di età 12-15 anni. Comunicato AIFA n. 681 5 gennaio 2022, available at  
[https://www.aifa.gov.it/documents/20142/1618244/Comunicato\\_AIFA\\_N.681.pdf](https://www.aifa.gov.it/documents/20142/1618244/Comunicato_AIFA_N.681.pdf)

7 COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU | European Medicines Agency. Accessed February 4, 2022

<https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-children-aged-12-17-eu>

8 La Commissione Tecnico Scientifica di AIFA (CTS) approva l'utilizzo del vaccino Spikevax (Moderna) per la fascia di età 12-17 anni. Comunicato AIFA n. 656 28 luglio 2021, available at [https://www.aifa.gov.it/documents/20142/1289678/Comunicato\\_AIFA\\_656.pdf](https://www.aifa.gov.it/documents/20142/1289678/Comunicato_AIFA_656.pdf)

9 Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 | European Medicines Agency. Accessed February 4, 2022.

<https://www.ema.europa.eu/en/news/comirnaty-covid-19-vaccine-ema-recommends-approval-children-aged-5-11>

10 La Commissione Tecnico Scientifica di AIFA (CTS) approva il vaccino Comirnaty per la fascia di età 5-11 anni. Comunicato AIFA n. 674 1 dicembre 2021, available at

[https://www.aifa.gov.it/documents/20142/1289678/Comunicato\\_AIFA\\_674.pdf](https://www.aifa.gov.it/documents/20142/1289678/Comunicato_AIFA_674.pdf)